Three Schedules of Recombinant Human Interleukin‐2 in the Treatment of Malignancy: Side Effects and Immunologic Effects in Relation to Serum Level

Recombinant human interleukin‐2 (rIL‐2) was administered to 34 patients with advanced malignancy. Three schedules of rIL‐2 administration employed were as follows: (A) 2‐hr iv infusion of 6.7 × 10(*5) U/m(*2)/day (A(1), 6 cases) or 2.2 × 10(*6) U/m(*2)/day (A(2), 8 cases) for five consecutive days;...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Jpn J Cancer Res
Autors principals: Sano, Tetsuro, Saijo, Nagahiro, Sasaki, Yasutsuna, Shinkai, Tetsu, Eguchi, Kenji, Tamura, Tomohide, Sakurai, Masanori, Takahashi, Hidenobu, Nakano, Hidehiko, Nakagawa, Kazuhiko, Hong, Weon‐Seon
Format: Artigo
Idioma:Inglês
Publicat: Blackwell Publishing Ltd 1988
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5907760/
https://ncbi.nlm.nih.gov/pubmed/3128501
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1349-7006.1988.tb00020.x
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars